Septerna just entered the clinic, and its lack of human data makes it an outlier among the companies able to successfully go public this year in what is still a cautious biotech IPO market. What the ...
On Monday, HC Wainwright initiated coverage on Septerna, Inc. (NASDAQ:SEPN), citing a next-generation drug design platform aimed at hitherto-undruggable targets. Septerna is working on G ...
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug ...
We recently compiled a list of the 10 Best Rebound Stocks To Invest In Now. In this article, we are going to take a look at ...
For scientists developing new drugs, it’s hard to go wrong targeting a family of receptors that regulate virtually every known process in human beings. G protein-coupled receptors (GPCRs) are found ...
Septerna, Inc. recently reported third-quarter 2025 earnings, revealing a surge in sales to US$21.5 million and a shift from a net loss to net income compared to the same period last year. Following ...
Analysts' ratings for Septerna (NASDAQ:SEPN) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a snapshot of their recent ratings, showcasing how ...
Hosted on MSN
Septerna, Inc. (SEPN): Among The Stocks With At Least $30 Million In Insider Spending Recently
We recently compiled a list of the 10 Stocks With At Least $30 Million In Insider Spending Recently. In this article, we are going to take a look at where Septerna, Inc. (NASDAQ:SEPN) stands against ...
Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company’s innovative GPCR ...
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for ...
Septerna, Inc. (SEPN) shares soared 7% in the last trading session to close at $22.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback